Treatable Traits. Why, What, How?
octubre 15, 2025
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
Charla de Alvar Agistí en el H. La Paz sobre los orígenes de las enfermedades crónicas. tempranos en la sesión titulada: Orígenes tempranos de las enfermedades crónicas del adulto. El 24/09/2025
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Study highlights the role of cellular senescence markers (p16, p21) and MMP-7 co-expression in fibrosing interstitial lung diseases.
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Research on idiopathic pulmonary fibrosis reveals how immune infiltrate differences in early stages influence disease progression. Study highlights the role of B cells, T cells, and NK cells as potential biomarkers.
Expert consensus on patient-centred strategies to manage multimorbidity in COPD, aiming to improve outcomes and reduce disease burden.
The CAAT is a standardized 8-item questionnaire to assess health status in people with asthma, COPD, and other airway diseases. Now validated beyond COPD.
Commentary in the European Respiratory Journal (June 2025) reaffirming spirometry as the essential diagnostic tool for COPD.
Study analyzing risk factors and one-year outcomes of organizing pneumonia in COVID-19 hospitalized patients, evaluating the impact of corticosteroid treatment at different doses.